Intended for healthcare professionals

  1. News & Views
  2. Disclosure UK:...
  3. Disclosure UK: transparency should no longer be an optional extra
Editorials

Disclosure UK: transparency should no longer be an optional extra

BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3730 (Published 06 July 2016) Cite this as: BMJ 2016;354:i3730
Read all the latest BMJ articles on Disclosure UK and view the linked infographics here.

Related articles

Read all the latest BMJ articles on Disclosure UK

See more

Cited by...

  • Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
  • Awareness and perceptions among members of a Japanese cancer patient advocacy group concerning the financial relationships between the pharmaceutical industry and physicians: a mixed-methods analysis of survey data
  • Are conflict of interest declarations appropriate to allow sufficient consideration of potential bias in presentations?
  • Exposing drug industry funding of UK patient organisations
  • Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment
  • Patient organizations and conflict of interest
  • Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industrys Disclosure UK database, 2015 and 2016 cohorts
  • Report from the national data guardian for health and care
  • Should all doctors publicly declare payments from drug firms?
Back to top